Patient withdrawal occurred due to death, surgery, change of opioid, systemic opioid withdrawal symptoms or therapy-resistant vomiting. There were no significant changes in analgesic dose or pain intensity scores during the trial. Some patients experienced localized sensations of mild to moderate abdominal propulsions or cramps shortly after naloxone administration. A careful balance must be struck to allow for the optimal laxative effect of naloxone without compromising the analgesic properties of the opioid. Meissner W, Schmidt U, Hartmann M, et al.
Oral naloxone reverses opioid-associated constipation.
Patients were then followed for 12 months. Both groups achieved similar metabolic control, although the effects of both drugs diminished during the course of the study. In the small group of subjects who had been previously controlled with diet, the blood glucose-lowering effect of glyburide was slightly better than repaglinide. Repaglinide is a novel oral hypoglycemic agent that is as safe and effective.